Two-year disease remission of an unresectable basaloid thymic carcinoma with second line chemotherapy drugs: report of a case

Thymic carcinomas are extremely infrequent neoplasms (15% of all thymic epithelial tumors). Basaloid carcinoma is a peculiar tumor that represents no more than 2% of those infrequent thymic carcinomas. Surgical excision is the recommended treatment. As it's extremely rare, there is no evidence...

Descripción completa

Detalles Bibliográficos
Autores principales: Buero, Agustín, Quadrelli, Silvia, Pankl, Leonardo German, Vigovich, Felix
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The African Field Epidemiology Network 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6689853/
https://www.ncbi.nlm.nih.gov/pubmed/31448016
http://dx.doi.org/10.11604/pamj.2019.33.53.12401
Descripción
Sumario:Thymic carcinomas are extremely infrequent neoplasms (15% of all thymic epithelial tumors). Basaloid carcinoma is a peculiar tumor that represents no more than 2% of those infrequent thymic carcinomas. Surgical excision is the recommended treatment. As it's extremely rare, there is no evidence of the impact of different modalities of treatment. There are no reported cases that did not include surgery as part of their management. We herein present a case of an unresectable thymic basaloid carcinoma treated only with concurrent chemotherapy and radiotherapy that obtained a complete remission and free of disease after 2 years.

Ejemplares similares